Hepatic structural dosimetry in 90Y microsphere treatment: A Monte Carlo modeling approach based on lobular microanatomy

Journal of Nuclear Medicine

Volumn 51, Issue 2, 2010, Pages 301-310

  Gulec, Seza A ^a   Sztejnberg, Manuel L ^b   Siegel, Jeffry A ^c   Jevremovic, Tatjana ^b   Stabin, Michael ^d  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b Purdue University   (United States)

^c Nuclear Physics Enterprises   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

90Y microspheres; Hepatic structural dosimetry; Hepatology; MCNPX; Oncology; Radiobiology dosimetry; Radionuclide therapy; SIRT

Indexed keywords

MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; CENTRAL VEIN; DOSIMETRY; LIVER; LIVER FUNCTION; LIVER PARENCHYMA; LIVER STRUCTURE; LIVER TUMOR; MONTE CARLO METHOD; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION;

HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER; LIVER NEOPLASMS; MICROSPHERES; MODELS, STATISTICAL; MONTE CARLO METHOD; PHANTOMS, IMAGING; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; YTTRIUM RADIOISOTOPES;

EID: 75749093030     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.069278     Document Type: Article

References (30)

1. Gray B, Van Hazel G, Hope M, et al. Randomized trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711-1720.
2. Van Hazel G, Blackwell A, Anderson J, et al. Randomized phase 2 trial of SIRspheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/ leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78-85.
3. Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099-1106.
4. 90Y radiomicrosphere and chemotherapy combination treatment in patients with colorectal cancer liver metastases [abstract]. J Nucl Med. 2008;49(suppl 1):103P.
5. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with yttrium-90 microspheres for extensive colorectal cancer metastases. J Gastrointest Surg. 2001;5:294-302.
6. Kennedy A, Coldwell D, Nutting C, et al. Resin Y-90-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412-425.
7. 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583-592.
8. 90y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639.
9. 90Y- microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494-1500.
10. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind J-FH. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13:S223-S229.
11. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. New York, NY: The Society of Nuclear Medicine; 1988.
12. Lautt WW. Hepatic Circulation in Health and Disease. New York, NY: Raven Press Books Ltd.; 1981.
13. Sarfaraz M, Kennedy AS, Cao ZJ, et al. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys. 2003;30:199-203.
14. Guyton AC, Hall JE. Textbook of Medical Physiology. Philadelphia, PA: W.B. Saunders Company; 1996.
15. Pelowitz DB, ed. MCNPX™ - User's Manual, Version 2.5.0. Publication LACP-05-0369. Los Alamos, NM: Los Alamos National Laboratory; 2005.
16. Berger MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. MIRD pamphlet no. 7. J Nucl Med. 1971;12(suppl 5):5-23.
17. Cohen BL. Concepts of Nuclear Physics. New York, NY: McGraw-Hill; 1971.
18. Enge H. Introduction to Nuclear Physics. Reading, MA: Addison Wesley; 1970.
19. International Commission on Radiation Units and Measurements. Photon, Electron, Proton and Neutron Interaction Data for Body Tissues. ICRU Report 46. Bethesda, MD: International Commission on Radiation Units and Measurements; 1992.
20. Emami B, Brown JLA, Coia L, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
21. Ingold JA, Reed GB, Kaplan HS, et al. Radiation hepatitis. AJR. 1965;93:200-208.
22. Moroz P, Anderson JE, Van Hazel G, Gray BN. Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol. 2001;78:248-252.
23. Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol. 2008;19:691-697.
24. Ng SS, Yu SC, Lai PB, Lau WY. Biliary complications associated with selective internal radiation (SIR) therapy for unresectable liver malignancies. Dig Dis Sci. 2008;53:2813-2817.
25. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol. 2005;16:205-213.
26. 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:792-800.
27. Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947-952.
28. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293-298.
29. Gulec SA, Mesoloras G, Dezarn A, Kennedy AS. Safety and efficacy evaluation of Y-90 microsphere treatment using medical internal radiation dosimetry (MIRD) in patients with primary and metastatic liver cancer [abstract]. J Transl Med. 2007;5:15.
30. Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in Y-90 microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47:1209-1211.